This is a StreetInsider.com Premium Only Page

(DARE) –

Apr 23, 2024 08:03 AM Dare Bioscience (DARE) Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024 08:00 AM Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 17, 2024 12:24 PM Brookline Capital Markets Downgrades Dare Bioscience (DARE) to Hold

Apr 16, 2024 04:21 PM Form PRE 14A Dare Bioscience, Inc. For: Jun 05

Apr 11, 2024 08:00 AM Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intrava

Mar 29, 2024 04:07 PM Form S-3 Dare Bioscience, Inc.

Mar 29, 2024 04:07 PM Form S-3 Dare Bioscience, Inc.

Mar 28, 2024 04:07 PM Form 424B5 Dare Bioscience, Inc.

Mar 28, 2024 04:03 PM Form 10-K Dare Bioscience, Inc. For: Dec 31

Mar 28, 2024 08:05 AM Form 8-K Dare Bioscience, Inc. For: Mar 28

Mar 28, 2024 08:00 AM Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024 08:00 AM Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 14, 2024 04:39 PM Form 4 Dare Bioscience, Inc. For: Mar 12 Filed by: Fair John A

Mar 14, 2024 04:34 PM Form 4 Dare Bioscience, Inc. For: Mar 12 Filed by: JOHNSON SABRINA MARTUCCI

Mar 14, 2024 04:28 PM Form 4 Dare Bioscience, Inc. For: Mar 12 Filed by: Haring-Layton MarDee

Feb 22, 2024 08:00 AM Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Jan 31, 2024 08:05 AM Dare Bioscience (DARE) Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream

Jan 31, 2024 08:00 AM Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 29, 2024 04:19 PM Form 3 Dare Bioscience, Inc. For: Jan 26 Filed by: Haring-Layton MarDee

Jan 26, 2024 05:15 PM Form 8-K Dare Bioscience, Inc. For: Jan 23

Jan 26, 2024 04:34 PM Dare Bioscience (DARE) Announces Board Changes

Jan 26, 2024 04:30 PM Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 19, 2024 04:31 PM Form 8-K Dare Bioscience, Inc. For: Jan 17

Jan 17, 2024 08:05 AM Dare Bioscience (DARE) Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024 08:00 AM Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 8, 2024 08:01 AM Form 8-K Dare Bioscience, Inc. For: Jan 08

Jan 4, 2024 08:07 AM Dare Bioscience (DARE) DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024 08:00 AM Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023 04:05 PM Form D Dare Bioscience, Inc.

Dec 26, 2023 08:06 AM Form 8-K Dare Bioscience, Inc. For: Dec 21

Dec 26, 2023 08:00 AM Dare Bioscience (DARE) Secures $12M in Royalty-backed Investment Structure

Dec 26, 2023 08:00 AM Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023 08:06 AM Form 8-K Dare Bioscience, Inc. For: Dec 20

Dec 20, 2023 08:02 AM Dare Bioscience (DARE) Reports Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Study

Dec 20, 2023 08:00 AM Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 13, 2023 08:01 AM Dare Bioscience (DARE) Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DA

Dec 13, 2023 08:00 AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB

Dec 7, 2023 08:08 AM Dare Bioscience (DARE) Announces FDA Clearance of IND Application for DARE-VVA1

Dec 7, 2023 08:00 AM Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vul

Dec 4, 2023 08:00 AM Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Nov 20, 2023 08:00 AM Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Nov 13, 2023 08:00 AM Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Nov 9, 2023 05:15 PM Form 8-K Dare Bioscience, Inc. For: Nov 09

Nov 9, 2023 04:03 PM Form 10-Q Dare Bioscience, Inc. For: Sep 30

Nov 9, 2023 08:06 AM Form 8-K Dare Bioscience, Inc. For: Nov 09

Nov 9, 2023 08:00 AM Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 6, 2023 08:00 AM Daré Bioscience to Participate in Three November Conferences

Nov 2, 2023 08:00 AM Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

Nov 1, 2023 08:06 AM Form 8-K Dare Bioscience, Inc. For: Nov 01

Nov 1, 2023 08:01 AM Dare Bioscience (DARE) Reports Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream